These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20358447)

  • 1. Response to letter to the editor: Statistical issues of QT prolongation assessment based on linear concentration modeling by Yi Tsong et al.
    Wang Y; Garnett C
    J Biopharm Stat; 2010 May; 20(3):689-92; author reply 693-7. PubMed ID: 20358447
    [No Abstract]   [Full Text] [Related]  

  • 2. Revisit the combination validation test of Tsong et al. for thorough QT/QTc clinical trials.
    Sun GG; Quan H
    J Biopharm Stat; 2010 May; 20(3):683-7; author reply 688. PubMed ID: 20358445
    [No Abstract]   [Full Text] [Related]  

  • 3. Statistical characteristics of moxifloxacin-induced QTc effect.
    Yan LK; Zhang J; Ng MJ; Dang Q
    J Biopharm Stat; 2010 May; 20(3):497-507. PubMed ID: 20358432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A statistical assessment of QT data following placebo and moxifloxacin dosing in thorough QT studies.
    Stylianou A; Roger J; Stephens K
    J Biopharm Stat; 2008; 18(3):502-16. PubMed ID: 18470759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statistical consideration in testing for assay sensitivity in a "thorough" QT study.
    Sethuraman V; Wu S; Wang J
    J Biopharm Stat; 2010 May; 20(3):641-53. PubMed ID: 20358442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical issues of QT prolongation assessment based on linear concentration modeling.
    Tsong Y; Shen M; Zhong J; Zhang J
    J Biopharm Stat; 2008; 18(3):564-84. PubMed ID: 18470764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A nonparametric approach to QT interval correction for heart rate.
    Wang D; Cheung YB; Arezina R; Taubel J; Camm AJ
    J Biopharm Stat; 2010 May; 20(3):508-22. PubMed ID: 20358433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical characterization of QT prolongation.
    Schall R; Ring A
    J Biopharm Stat; 2010 May; 20(3):543-62. PubMed ID: 20358435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.
    Chen X; Cass JD; Bradley JA; Dahm CM; Sun Z; Kadyszewski E; Engwall MJ; Zhou J
    Br J Pharmacol; 2005 Nov; 146(6):792-9. PubMed ID: 16158069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrocardiographic method for identifying drug-induced repolarization abnormalities associated with a reduction of the rapidly activating delayed rectifier potassium current.
    Couderc JP; Vaglio M; Xia X; McNitt S; Hyrien O
    Conf Proc IEEE Eng Med Biol Soc; 2006; 2006():4010-5. PubMed ID: 17946595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arrhythmias associated with fluoroquinolone therapy.
    Falagas ME; Rafailidis PI; Rosmarakis ES
    Int J Antimicrob Agents; 2007 Apr; 29(4):374-9. PubMed ID: 17241772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reevaluation of moxifloxacin pharmacokinetics and their direct effect on the QT interval.
    Grosjean P; Urien S
    J Clin Pharmacol; 2012 Mar; 52(3):329-38. PubMed ID: 21415283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of beat-to-beat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil.
    Fossa AA; Langdon G; Couderc JP; Zhou M; Darpo B; Wilson F; Wallis R; Davis JD
    Clin Pharmacol Ther; 2011 Sep; 90(3):449-54. PubMed ID: 21814193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple comparisons of repeatedly measured response: issues of validation testing in thorough QT/QTc clinical trials.
    Tsong Y; Yan LK; Zhong J; Nie L; Zhang J
    J Biopharm Stat; 2010 May; 20(3):654-64. PubMed ID: 20358443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation testing in thorough QT/QTc clinical trials.
    Tsong Y; Zhong J; Chen WJ
    J Biopharm Stat; 2008; 18(3):529-41. PubMed ID: 18470761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
    Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF
    Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple comparisons of repeated measured response: issues of assessment of prolongation of QT interval in thorough QT trials.
    Tsong Y; Zhong J
    J Biopharm Stat; 2010 May; 20(3):604-14. PubMed ID: 20358439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Practical ECG problems in the elderly patient. Case number 16. Moxifloxacin-associated QT interval prolongation].
    Farhoumand AD; Trombert V; Eusebio J
    Rev Med Suisse; 2011 Mar; 7(286):624-5. PubMed ID: 21510347
    [No Abstract]   [Full Text] [Related]  

  • 19. Moxifloxacin-induced torsades de pointes.
    Sherazi S; DiSalle M; Daubert JP; Shah AH
    Cardiol J; 2008; 15(1):71-3. PubMed ID: 18651388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the average baseline versus the time-matched baseline in parallel group thorough QT/QTc studies.
    Meng Z; Quan H; Fan L; Kringle R; Sun G
    J Biopharm Stat; 2010 May; 20(3):665-82. PubMed ID: 20358444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.